NCT02096692

Brief Summary

The objective of the ProMRI Study is to demonstrate the clinical safety of the ProMRI ICD System when used under specific MRI conditions.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
154

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2014

Shorter than P25 for all trials

Geographic Reach
1 country

39 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 24, 2014

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 26, 2014

Completed
2 months until next milestone

Study Start

First participant enrolled

June 1, 2014

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2015

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2015

Completed
5 months until next milestone

Results Posted

Study results publicly available

October 22, 2015

Completed
Last Updated

February 29, 2016

Status Verified

February 1, 2016

Enrollment Period

9 months

First QC Date

March 24, 2014

Results QC Date

September 18, 2015

Last Update Submit

February 1, 2016

Conditions

Outcome Measures

Primary Outcomes (3)

  • MRI and ICD System Related Serious Adverse Device Effect (SADE) Free Rate

    1 Month Post-MRI

  • Percentage of Participants Free of Ventricular Pacing Threshold Rise

    Evaluate the percentage of ICD leads free of ventricular pacing threshold increase between the Pre-MRI and one-month post-MRI follow-up.

    Between Pre-MRI and 1 Month Post-MRI

  • Percentage of Participants Free of R-wave Sensing Attenuation

    Evaluate the percentage of subjects free of R-wave attenuation between the Pre-MRI and one-month post-MRI follow-up.

    Between Pre-MRI and 1 Month Post-MRI

Study Arms (1)

ICD System Therapy

Patients with a ProMRI ICD System

Device: Patients with a ProMRI ICD SystemOther: Magnetic Resonance Imaging (MRI) scan

Interventions

Tachycardia Fast Heart Beat

ICD System Therapy

MRI scan of heart/chest or thoracic spine

ICD System Therapy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The patients selected for participation should be from the investigators' general patient population according to the inclusion and exclusion criteria.

You may qualify if:

  • Age greater than or equal to 18 years
  • Able and willing to complete MRI testing
  • Able to provide written informed consent
  • Available for follow-up visit at the study site
  • Implanted with an ICD System consisting only of an Iforia DR-T and Linoxsmart S 65 / Linoxsmart SD 65/18 with Setrox S 53 atrial lead or Iforia VR-T DX and Linoxsmart S DX 65/15 or Linoxsmart S DX 65/17.
  • ICD implanted pectorally
  • All ICD system components implanted, repositioned, or exchanged at least 5 weeks prior to enrollment
  • Underlying rhythm identifiable during sensing test
  • All pacing thresholds are measureable and are less than or equal to 2.0 V @ 0.4 ms (Criterion does not apply to atrial pacing threshold for subjects with an Iforia DR-T that have AF and are permanently programmed to VVI and for subjects with an Iforia VR-T DX)
  • Ventricular sensing is measurable and \>6.5mV
  • Absence of phrenic nerve stimulation at 5.0V and 1.0 ms
  • Pacing impedance is between 200 and 1500 ohm
  • Shock Impedance is between 30 and 90 ohm
  • Able and willing to use the CardioMessenger II
  • At the pre-MRI procedure, the following procedure-related criteria must be met for the subject to undergo the MRI scan:
  • +9 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (39)

Unknown Facility

Birmingham, Alabama, 35294, United States

Location

Unknown Facility

Phoenix, Arizona, 85018, United States

Location

Unknown Facility

Scottsdale, Arizona, 85251, United States

Location

Unknown Facility

Concord, California, 94520, United States

Location

Unknown Facility

Newport Beach, California, 92663, United States

Location

Unknown Facility

Rancho Mirage, California, 92270, United States

Location

Unknown Facility

New Haven, Connecticut, 06510, United States

Location

Unknown Facility

Newark, Delaware, 19702, United States

Location

Unknown Facility

Washington D.C., District of Columbia, 20010, United States

Location

Unknown Facility

Valparasio, Indiana, 46383, United States

Location

Unknown Facility

Iowa City, Iowa, 52242, United States

Location

Unknown Facility

Lafayette, Louisiana, 70503, United States

Location

Unknown Facility

Cumberland, Maryland, 21502, United States

Location

Unknown Facility

Takoma Park, Maryland, 20912, United States

Location

Unknown Facility

Boston, Massachusetts, 02114, United States

Location

Unknown Facility

Burlington, Massachusetts, 01805, United States

Location

Unknown Facility

Worcester, Massachusetts, 01655, United States

Location

Unknown Facility

Ann Arbor, Michigan, 48109, United States

Location

Unknown Facility

Grand Rapids, Michigan, 49506, United States

Location

Unknown Facility

Ypsilanti, Michigan, 48197, United States

Location

Unknown Facility

Kansas City, Missouri, 94520, United States

Location

Unknown Facility

St Louis, Missouri, 63110, United States

Location

Unknown Facility

Flushing, New York, 11355, United States

Location

Unknown Facility

New York, New York, 10016, United States

Location

Unknown Facility

New York, New York, 10021, United States

Location

Unknown Facility

The Bronx, New York, 10463, United States

Location

Unknown Facility

Winston-Salem, North Carolina, 27157, United States

Location

Unknown Facility

Columbus, Ohio, 43210, United States

Location

Unknown Facility

Toledo, Ohio, 43615, United States

Location

Unknown Facility

Portland, Oregon, 97225, United States

Location

Unknown Facility

Salem, Oregon, 97301, United States

Location

Unknown Facility

Langhorne, Pennsylvania, 08691, United States

Location

Unknown Facility

Wynnewood, Pennsylvania, 19096, United States

Location

Unknown Facility

Greenville, South Carolina, 29615, United States

Location

Unknown Facility

Nashville, Tennessee, 37232, United States

Location

Unknown Facility

Amarillo, Texas, 79106, United States

Location

Unknown Facility

Mechanicsville, Virginia, 23116, United States

Location

Unknown Facility

Virginia Beach, Virginia, 23454, United States

Location

Unknown Facility

Spokane, Washington, 99204, United States

Location

Related Publications (1)

  • Awad K, Griffin J, Crawford TC, Lane Cox S, Ferrick K, Mazur A, Pena RE, Lloyd SG, Michalski J, Johnson W, Bailey WM. Clinical safety of the Iforia implantable cardioverter-defibrillator system in patients subjected to thoracic spine and cardiac 1.5-T magnetic resonance imaging scanning conditions. Heart Rhythm. 2015 Oct;12(10):2155-61. doi: 10.1016/j.hrthm.2015.06.002. Epub 2015 Jun 3.

MeSH Terms

Interventions

Magnetic Resonance Spectroscopy

Intervention Hierarchy (Ancestors)

Spectrum AnalysisChemistry Techniques, AnalyticalInvestigative Techniques

Results Point of Contact

Title
Clinical Studies Engineer
Organization
Biotronik, Inc.

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 24, 2014

First Posted

March 26, 2014

Study Start

June 1, 2014

Primary Completion

March 1, 2015

Study Completion

June 1, 2015

Last Updated

February 29, 2016

Results First Posted

October 22, 2015

Record last verified: 2016-02

Locations